Pattern of emergence of resistance mutations among participants who selected A360V.

aSample obtained at earliest available time point after treatment initiation and which mutations were present compared with the pre-therapy sample.bSample obtained at time point of last-on-therapy sample available. Participants 3 and 4 reached a study endpoint. Participants 6, 11, 29 and 31 did not reach a study end-point.cFor participants 6 and 11, mutation A360V occurred in